CERo Therapeutics Stock (NASDAQ:CERO)

Ownership Financials Chart

Previous Close

$0.24

52W Range

$0.06 - $12.80

50D Avg

$0.11

200D Avg

$1.14

Market Cap

$38.79M

Avg Vol (3M)

$63.12M

Beta

-0.46

Div Yield

-

CERO Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Nov 30, 2021

Website

CERO Performance

CERO Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-2.93M	$-2.91M	$-332.03K
Net Income	$-2.54M	$-667.74K	$-315.55K
EBITDA	$-2.93M	$-2.91M	$-332.03K
Basic EPS	$-0.39	$-0.10	$-0.01
Diluted EPS	$-0.39	$-0.10	$-0.01

Fiscal year ends in Dec 23 | Currency in USD